Literature DB >> 28506500

Autonomic and electrocardiographic findings in Parkinson's disease.

Christopher H Gibbons1, David K Simon2, Meilin Huang3, Barbara Tilley3, Michael J Aminoff4, Jacquelyn L Bainbridge5, Matthew Brodsky6, Roy Freeman2, John Goudreau7, Robert W Hamill8, Sheng T Luo3, Carlos Singer9, Aleksandar Videnovic10, Ivan Bodis-Wollner11, Pei S Wong12.   

Abstract

Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms and signs. Many reports suggest that diminished heart rate variability occurs early, even prior to the cardinal signs of PD. In a longitudinal study of PD, we evaluated whether heart rate variability (HRV) obtained using a 10-second ECG tracing, and the electrocardiographic QT-interval would be associated with PD severity and progression. Subjects were derived from a longitudinal study of 1741 individuals with early, stable PD. The severity of PD was measured using the global statistical test (GST). In a subset, the heart rate corrected QT-interval (QTcB) was calculated for each electrocardiogram (ECG). The HRV was measured for each ECG and then transformed to fit a normal distribution. The baseline analysis included 653 subjects, with 256 completing the 5-year follow up study. There was an association (P<0.05) between QTcB and PD severity in individuals that were taking QT-interval affecting drugs. A longer QT-interval at baseline was associated with more advanced PD at 5years (P<0.05), and greater disease progression over 5years (P<0.05). There was an association between diminished HRV and an orthostatic decrease in standing blood pressure at baseline in individuals with PD (P<0.05). HRV was not associated with PD severity or progression. In conclusion, we were able to detect measurable associations between the QTcB interval and PD severity, PD severity 5years later, and the change in disease over time. However, routine ECG tracings appear inadequate for the evaluation of autonomic function in PD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autonomic; Electrocardiogram; Heart rate variability; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28506500      PMCID: PMC5609844          DOI: 10.1016/j.autneu.2017.04.002

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  19 in total

Review 1.  Autonomic involvement in Parkinson's disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers.

Authors:  Maria G Cersosimo; Eduardo E Benarroch
Journal:  J Neurol Sci       Date:  2011-10-14       Impact factor: 3.181

2.  Determinants of heart rate variability.

Authors:  H Tsuji; F J Venditti; E S Manders; J C Evans; M G Larson; C L Feldman; D Levy
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

4.  Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Authors:  Sotirios A Parashos; Sheng Luo; Kevin M Biglan; Ivan Bodis-Wollner; Bo He; Grace S Liang; G Webster Ross; Barbara C Tilley; Lisa M Shulman
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

5.  [Prolonged QTc intervals in Parkinson's disease--relation to sudden death and autonomic dysfunction].

Authors:  F Ishizaki; T Harada; H Yoshinaga; T Nakayama; Y Yamamura; S Nakamura
Journal:  No To Shinkei       Date:  1996-05

6.  Is cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study.

Authors:  Jose-Alberto Palma; Maria-Mar Carmona-Abellan; Noelia Barriobero; Cristina Trevino-Peinado; Martin Garcia-Lopez; Elena Fernandez-Jarne; Maria R Luquin
Journal:  Mov Disord       Date:  2013-03-11       Impact factor: 10.338

7.  Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Authors:  Jordan J Elm
Journal:  Mov Disord       Date:  2012-10       Impact factor: 10.338

Review 8.  Outcomes of screening Parkinson's patients for QTc prolongation.

Authors:  Anne-Louise Cunnington; Kay Hood; Lesley White
Journal:  Parkinsonism Relat Disord       Date:  2013-07-17       Impact factor: 4.891

9.  Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity.

Authors:  J G van Dijk; J Haan; K Zwinderman; B Kremer; B J van Hilten; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

10.  Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  Kazushi Deguchi; Iwao Sasaki; Masago Tsukaguchi; Masashi Kamoda; Tetsuo Touge; Hiroaki Takeuchi; Shigeki Kuriyama
Journal:  J Neurol Sci       Date:  2002-07-15       Impact factor: 3.181

View more
  6 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  Pilot Study for Correlation of Heart Rate Variability and Dopamine Transporter Brain Imaging in Patients with Parkinsonian Syndrome.

Authors:  Devdutta S Warhadpande; Jiayan Huo; William A Libling; Carol Stuehm; Bijan Najafi; Scott Sherman; Hong Lei; Janet Meiling Roveda; Phillip H Kuo
Journal:  Sensors (Basel)       Date:  2022-07-05       Impact factor: 3.847

Review 3.  QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.

Authors:  Yasar Torres-Yaghi; Amelia Carwin; Jacob Carolan; Steven Nakano; Fahd Amjad; Fernando Pagan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-24       Impact factor: 2.570

Review 4.  Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease.

Authors:  Marli Cardoso Martins-Pinge; Lorena de Jager; Blenda Hyedra de Campos; Lorena Oliveira Bezerra; Pamela Giovana Turini; Phileno Pinge-Filho
Journal:  Front Pharmacol       Date:  2022-07-11       Impact factor: 5.988

5.  Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.

Authors:  Valeria C Gonçalves; Daniel J L L Pinheiro; Tomás de la Rosa; Antônio-Carlos G de Almeida; Fúlvio A Scorza; Carla A Scorza
Journal:  Nutrients       Date:  2020-05-26       Impact factor: 5.717

6.  Prevalence of QTc Prolongation in Patients with Parkinson's Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula.

Authors:  Jakub J Malkiewicz; Maciej Malkiewicz; Joanna Siuda
Journal:  J Clin Med       Date:  2021-03-31       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.